PolyNovo (PNV) Stock Overview
Designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PNV from our risk checks.
PNV Community Fair Values
Create NarrativeSee what 66 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.99 |
| 52 Week High | AU$1.67 |
| 52 Week Low | AU$0.86 |
| Beta | 1.35 |
| 1 Month Change | -5.69% |
| 3 Month Change | 5.85% |
| 1 Year Change | -12.33% |
| 3 Year Change | -31.85% |
| 5 Year Change | -56.74% |
| Change since IPO | 397.50% |
Recent News & Updates
Narrative Update • Jun 15
PNV: Refined Cash Flow Assumptions Will Support Steady Outlook And Balanced Upside Potential
Analysts have modestly revised their fair value outlook for PolyNovo, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. Together, these factors support a slightly adjusted A$ price target and a more refined view of the stock’s long term earnings profile.
Narrative Update • Jun 01
PNV: Higher Discount Rate And P/E Framework Will Support Future Upside Potential
Analysts have trimmed their price target for PolyNovo to A$1.70 from A$1.98, reflecting updated views on the stock's fair value, discount rate, expected revenue growth, profit margins and future P/E assumptions. What's in the News Analysts updated their valuation work on PolyNovo, which led to a revision of the price target to A$1.70.Narrative Update • Apr 24
PNV: Fine Tuned Assumptions Will Support Stable Outlook And Balanced Upside Potential
Analysts have adjusted their A$ price target on PolyNovo, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. You should view this as a fine tuning of their outlook rather than a major reset.Narrative Update • Apr 10
PNV: Higher Margin Outlook And Adjusted Assumptions Will Support Balanced Upside Potential
Analysts have lifted their price target on PolyNovo to A$X.X0 from A$Y.Y0. The change reflects slightly higher assumptions for long term revenue growth and profit margins, a modestly higher discount rate, and a marginally lower future P/E multiple.Recent updates
Narrative Update • Jun 15
PNV: Refined Cash Flow Assumptions Will Support Steady Outlook And Balanced Upside Potential
Analysts have modestly revised their fair value outlook for PolyNovo, reflecting updated assumptions around the discount rate, revenue growth, profit margin and future P/E. Together, these factors support a slightly adjusted A$ price target and a more refined view of the stock’s long term earnings profile.Narrative Update • Jun 01
PNV: Higher Discount Rate And P/E Framework Will Support Future Upside Potential
Analysts have trimmed their price target for PolyNovo to A$1.70 from A$1.98, reflecting updated views on the stock's fair value, discount rate, expected revenue growth, profit margins and future P/E assumptions. What's in the News Analysts updated their valuation work on PolyNovo, which led to a revision of the price target to A$1.70.Narrative Update • Apr 24
PNV: Fine Tuned Assumptions Will Support Stable Outlook And Balanced Upside Potential
Analysts have adjusted their A$ price target on PolyNovo, reflecting updated assumptions for discount rate, revenue growth, profit margin and future P/E. You should view this as a fine tuning of their outlook rather than a major reset.Narrative Update • Apr 10
PNV: Higher Margin Outlook And Adjusted Assumptions Will Support Balanced Upside Potential
Analysts have lifted their price target on PolyNovo to A$X.X0 from A$Y.Y0. The change reflects slightly higher assumptions for long term revenue growth and profit margins, a modestly higher discount rate, and a marginally lower future P/E multiple.Narrative Update • Mar 26
PNV: Higher Margin Outlook And Steady P E Assumption Will Support Upside Potential
Analysts have slightly increased their A$ price target for PolyNovo, citing updated assumptions for revenue growth, profit margins and future P/E that together support a modestly higher valuation outlook. Valuation Changes Fair Value: A$ fair value input is unchanged at 1.0. Discount Rate: Discount rate has edged down slightly from 7.58% to 7.58%.Narrative Update • Mar 11
PNV: Refined Profitability And P E Assumptions Will Support Balanced Future Returns
Analysts have slightly adjusted their valuation work on PolyNovo, trimming the implied P/E multiple and updating growth and profitability assumptions. This has led to a modest change in their A$ price target while keeping the overall fair value view broadly in line with prior estimates.Narrative Update • Feb 25
PNV: Updated Profitability Assumptions Will Support Balanced Future Return Potential
Analysts have revised their PolyNovo price target from A$1.25 to A$1.00, citing updated assumptions for revenue growth, margins, and future P/E that they view as more consistent with current expectations. Valuation Changes Fair Value: Reduced from A$1.25 to A$1.00, which implies a lower central estimate for the share price.Narrative Update • Feb 10
PNV: Refined Earnings Assumptions Will Support Steady Fair Value Upside
Analysts have reaffirmed their A$1.25 price target for PolyNovo, with only slight tweaks to the discount rate, revenue growth, profit margin and assumed future P/E. This reflects fine tuning of their valuation rather than a major change in view.Analysis Article • Feb 07
PolyNovo Limited (ASX:PNV) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
PolyNovo Limited ( ASX:PNV ) shareholders that were waiting for something to happen have been dealt a blow with a 27...Narrative Update • Jan 27
PNV: Earnings Outlook Will Support Steady Fair Value And Upside Potential
Analysts have kept their PolyNovo fair value unchanged at A$1.25, with small tweaks to assumptions for discount rate, revenue growth, profit margin and future P/E, reflecting slightly updated views on the risk profile and earnings outlook. Valuation Changes Fair Value: Kept unchanged at A$1.25 per share, indicating no change to the anchor valuation level.Narrative Update • Jan 12
PNV: Revenue Outlook And Margins Will Support Steady Fair Value Expectations
Analysts have kept their price target for PolyNovo unchanged at A$1.25. Slight adjustments to assumptions for discount rate, revenue growth, profit margin and future P/E multiple have contributed to maintaining this view.Narrative Update • Dec 13
PNV: Revenue Outlook And Margins Will Support Measured Future Share Performance
Analysts have modestly raised their price target on PolyNovo from A$1.20 to A$1.25, citing expectations for faster revenue growth, slightly higher profit margins, and a marginally lower future P E multiple despite a small increase in the discount rate. Valuation Changes Fair Value: Risen slightly from A$1.20 to A$1.25, reflecting a modest uplift in the central valuation estimate.Narrative Update • Nov 29
PNV: Future P/E and Discount Rate Shift Will Support Upside Momentum
Analysts have raised their price target for PolyNovo from $1.97 to $1.98 per share, citing slight adjustments to the discount rate and future price-to-earnings assumptions. What's in the News PolyNovo Limited (ASX:PNV) has been dropped from the S&P/ASX 200 Index (Key Developments) Valuation Changes Fair Value: Increased marginally to A$1.98 per share from A$1.97.Narrative Update • Nov 15
PNV: Discount Rate Adjustment Will Support Positive Investor Sentiment
Analysts have slightly raised their price target for PolyNovo to $1.97. They cited minor adjustments to the company's discount rate while maintaining their outlook on revenue growth and profit margins.Narrative Update • Nov 01
PNV: Improved Margins And Expansion Efforts Will Drive Future Upside
Analysts have maintained their price target for PolyNovo at $1.97, reflecting a largely unchanged outlook. Modest improvements in revenue growth and profit margin offset a slight increase in discount rate assumptions.Narrative Update • Oct 18
International Expansion And Regulatory Approvals Will Unlock New Markets
Analysts have maintained PolyNovo's fair value price target at $1.97. This reflects continued confidence in the company's prospects despite minor adjustments to certain financial assumptions.Narrative Update • Oct 04
International Expansion And Regulatory Approvals Will Unlock New Markets
Analysts have raised their fair value price target for PolyNovo from $1.81 to $1.97 per share. This change reflects slight improvements in projected revenue growth and a marginally lower discount rate.Analysis Article • Sep 28
At AU$1.38, Is PolyNovo Limited (ASX:PNV) Worth Looking At Closely?
While PolyNovo Limited ( ASX:PNV ) might not have the largest market cap around , it led the ASX gainers with a...Analysis Article • Sep 11
PolyNovo Limited (ASX:PNV) Stocks Shoot Up 26% But Its P/E Still Looks Reasonable
The PolyNovo Limited ( ASX:PNV ) share price has done very well over the last month, posting an excellent gain of 26...Narrative Update • Aug 26
NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects
The consensus price target for PolyNovo has been revised downward to A$1.80, reflecting a notable drop in its future P/E multiple despite an improvement in net profit margin. Valuation Changes Summary of Valuation Changes for PolyNovo The Consensus Analyst Price Target has fallen from A$1.98 to A$1.80.Analysis Article • Jul 18
Returns Are Gaining Momentum At PolyNovo (ASX:PNV)
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Analysis Article • Jun 13
An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 38% Undervalued
Key Insights PolyNovo's estimated fair value is AU$1.92 based on 2 Stage Free Cash Flow to Equity Current share price...Analysis Article • May 22
PolyNovo Limited's (ASX:PNV) 25% Jump Shows Its Popularity With Investors
Those holding PolyNovo Limited ( ASX:PNV ) shares would be relieved that the share price has rebounded 25% in the last...Analysis Article • May 08
Is There Now An Opportunity In PolyNovo Limited (ASX:PNV)?
PolyNovo Limited ( ASX:PNV ), is not the largest company out there, but it saw a significant share price rise of 51% in...
New Narrative • Mar 11
NovoSorb MTX Launch And Global Expansion Will Strengthen Future Business Prospects
Launch of NovoSorb MTX in the U.S. and geographic expansion could drive revenue growth and diversify revenue sources.Analysis Article • Mar 03
PolyNovo (ASX:PNV) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Investors were disappointed with PolyNovo Limited's ( ASX:PNV ) earnings, despite the strong profit numbers. We think...Analysis Article • Feb 26
PolyNovo Limited's (ASX:PNV) Share Price Is Still Matching Investor Opinion Despite 37% Slump
The PolyNovo Limited ( ASX:PNV ) share price has fared very poorly over the last month, falling by a substantial 37...Analysis Article • Feb 11
An Intrinsic Calculation For PolyNovo Limited (ASX:PNV) Suggests It's 39% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, PolyNovo fair value estimate is AU$2.98 PolyNovo is estimated...Analysis Article • Oct 10
Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?
PolyNovo Limited ( ASX:PNV ), is not the largest company out there, but it received a lot of attention from a...Analysis Article • Aug 28
PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analysis Article • Aug 06
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 19.1x PolyNovo Limited ( ASX:PNV ) is a stock to avoid...Analysis Article • May 08
PolyNovo Limited's (ASX:PNV) P/S Is On The Mark
You may think that with a price-to-sales (or "P/S") ratio of 18.9x PolyNovo Limited ( ASX:PNV ) is a stock to avoid...Analysis Article • Feb 28
When Should You Buy PolyNovo Limited (ASX:PNV)?
While PolyNovo Limited ( ASX:PNV ) might not have the largest market cap around , it received a lot of attention from a...Analysis Article • Feb 02
Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S
With a price-to-sales (or "P/S") ratio of 20.8x PolyNovo Limited ( ASX:PNV ) may be sending very bearish signals at the...Analysis Article • Jan 08
PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate
Key Insights PolyNovo's estimated fair value is AU$2.90 based on 2 Stage Free Cash Flow to Equity PolyNovo's AU$1.54...Analysis Article • Sep 22
Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysis Article • Jun 26
When Should You Buy PolyNovo Limited (ASX:PNV)?
PolyNovo Limited ( ASX:PNV ), might not be a large cap stock, but it saw significant share price movement during recent...Analysis Article • May 30
Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?
Key Insights PolyNovo's estimated fair value is AU$2.17 based on 2 Stage Free Cash Flow to Equity PolyNovo is estimated...Analysis Article • Apr 18
Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price
With a price-to-sales (or "P/S") ratio of 22.3x PolyNovo Limited ( ASX:PNV ) may be sending very bearish signals at the...Analysis Article • Mar 23
Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?
PolyNovo Limited ( ASX:PNV ), is not the largest company out there, but it received a lot of attention from a...Shareholder Returns
| PNV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 6.4% | 3.4% | 0.2% |
| 1Y | -12.3% | -42.1% | 1.8% |
Return vs Industry: PNV exceeded the Australian Medical Equipment industry which returned -42.1% over the past year.
Return vs Market: PNV underperformed the Australian Market which returned 1.8% over the past year.
Price Volatility
| PNV volatility | |
|---|---|
| PNV Average Weekly Movement | 9.1% |
| Medical Equipment Industry Average Movement | 9.7% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in AU Market | 16.7% |
| 10% least volatile stocks in AU Market | 4.0% |
Stable Share Price: PNV has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: PNV's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 301 | Bruce Peatey | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in Australia, New Zealand, the United States, the United Kingdom, Ireland, Singapore, India, and Hong Kong. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal matrix for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; Beta Cell implant, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| PNV fundamental statistics | |
|---|---|
| Market cap | AU$690.84m |
| Earnings (TTM) | AU$9.88m |
| Revenue (TTM) | AU$139.49m |
69.6x
P/E Ratio4.9x
P/S RatioIs PNV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PNV income statement (TTM) | |
|---|---|
| Revenue | AU$139.49m |
| Cost of Revenue | AU$17.54m |
| Gross Profit | AU$121.95m |
| Other Expenses | AU$112.07m |
| Earnings | AU$9.88m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.014 |
| Gross Margin | 87.43% |
| Net Profit Margin | 7.08% |
| Debt/Equity Ratio | 4.4% |
How did PNV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/08 16:00 |
| End of Day Share Price | 2026/07/08 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PolyNovo Limited is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Shane Storey | Canaccord Genuity |